Biological-medicine company Human BioPlazma Gyártó es Kereskedelmi Kft is making a HUF 5 billion (€19.05 million) capacity-expansion investment at its plant just northeast of Budapest, The Hungarian Investment and Trade Development Agency (ITD Hungary) informed MTI on Friday.
Human BioPlazma plans to complete the investment, which is expected to more than double the company's annual production capacity of plasma-based medications to 550,000 liters, in 2011. The company, which currently employs 140 people at its plant in Gödöllő, will hire around 60 new workers as a result of the investment. Human BioPlazma belongs to the Kedrion Group. (MTI-Econews)